6th March 2025
Cambridge Cognition Holdings plc
("Cambridge Cognition", the "Company" or the "Group")
CANTAB® demonstrates substantial value in one of the largest brain health studies ever conducted
Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, announces its involvement in one of the world's largest brain health studies, the Intuition Brain Health study1, demonstrating the significant value of its proprietary digital cognitive assessments.
On 4th March 2025, leading scientific journal Nature Medicine2 published results from the Intuition Brain Health study, sponsored by Biogen, Inc., in collaboration with Apple, Inc. The study enrolled a representative sample of 23,004 participants across the United States and relied on Cambridge Cognition's CANTAB platform for the core cognitive assessment.
Cambridge Cognition was selected as a partner for the study for its proven ability to deliver reliable digital cognitive measurements in remote settings, highlighting the platform's unique capabilities for large-scale, unsupervised cognitive evaluation. The study demonstrates the feasibility of large-scale, cognitive assessments using smartphones alongside smartwatch technology and the significant potential to make brain health monitoring widely accessible for the general population. This validates the sensitivity of Cambridge Cognition's technology for the measurement of brain health across the lifespan.
Rob Baker, Joint Managing Director and Chief Operating Officer, commented:
"The Intuition study powerfully validates CANTAB's accuracy at scale and reinforces our leadership in digital brain health. As healthcare systems increasingly turn to digital solutions to address urgent challenges, this represents a significant opportunity which we are well positioned to meet."
This study highlights a strategically significant market opportunity for Cambridge Cognition's cognitive assessment platform, and we will be continuing to thoroughly evaluate the commercial potential for real-world brain health monitoring applications using our industry-leading software solutions in the coming months.
Key highlights of the study:
| ● | Scalability & Accessibility: Emphasises CANTAB's proven ability to scale across diverse populations with high adherence across an extended period, making brain health monitoring widely accessible. |
| ● | Sensitivity to mild cognitive impairment (MCI): Highlights the impressive performance metrics in detecting mild cognitive impairment to reinforce Cambridge Cognition's leadership in cognitive assessment. |
| ● | Validation & Future Leadership: The Intuition study provides evidence of Cambridge Cognition's status as the preferred partner and leading innovator in changing the landscape of brain health assessments. |
2. https://www.nature.com/articles/s41591-024-03475-9#Sec16
Enquiries:
| |
Notes to Editors
About Cambridge Cognition
Cambridge Cognition is a brain health software group specializing in digital health products that advance brain health research and treatment.
The company offers four core products: CANTAB¨ assessments-providing scientifically validated, highly sensitive, precise, and objective measures of cognitive function correlated to neural networks; a flexible and proven eCOA platform with an extensive library of instruments, enabling efficient study setup and scalable data capture; rater training services that standardise assessment delivery and scoring across clinical trials and quality assurance tools that ensure data integrity by automatically detecting deviations in administration and scoring, saving time and money. These products collectively improve clinical trial outcomes, enable early patient identification, and enhance global efficiency in healthcare and pharmaceuticals.
For further information, visit: www.cambridgecognition.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
